- Stocks
- Healthcare
- NASDAQ: SAGE

Price (delayed)

$7.87

Market cap

$480.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.41

Enterprise value

$380.64M

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing

The company's debt has shrunk by 84% YoY and by 57% QoQ

Sage Therapeutics's EPS has increased by 25% YoY and by 12% from the previous quarter

SAGE's equity is down by 36% YoY and by 11% from the previous quarter

SAGE's quick ratio is down by 19% QoQ and by 9% YoY

What are the main financial stats of SAGE

Market
Valuations
Earnings

Shares outstanding

61.05M

Market cap

$480.47M

Enterprise value

$380.64M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.75

Price to sales (P/S)

4.9

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.91

Revenue

$97.24M

EBIT

-$445.67M

EBITDA

-$444.29M

Free cash flow

-$373.87M

Per share
Balance sheet
Liquidity

EPS

-$7.41

Free cash flow per share

-$6.18

Book value per share

$10.44

Revenue per share

$1.61

TBVPS

$11.52

Total assets

$697.11M

Total liabilities

$69.04M

Debt

$1.41M

Equity

$628.06M

Working capital

$617.77M

Debt to equity

0

Current ratio

9.95

Quick ratio

9.53

Net debt/EBITDA

0.22

Margins
Efficiency
Dividend

EBITDA margin

-456.9%

Gross margin

95.5%

Net margin

-458.3%

Operating margin

-496.6%

Return on assets

-54.1%

Return on equity

-60.4%

Return on invested capital

-72.2%

Return on capital employed

-71%

Return on sales

-458.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Sage Therapeutics stock price performed over time

Intraday

-1.75%

1 week

-12.17%

1 month

-33.08%

1 year

-63.85%

YTD

-63.68%

QTD

-27.53%

How have Sage Therapeutics's revenue and profit performed over time

Revenue

$97.24M

Gross profit

$92.84M

Operating income

-$482.9M

Net income

-$445.67M

Gross margin

95.5%

Net margin

-458.3%

The company's net margin has surged by 92% YoY and by 17% QoQ

Sage Therapeutics's operating margin has surged by 92% YoY and by 17% QoQ

The net income has increased by 25% year-on-year and by 11% since the previous quarter

Sage Therapeutics's operating income has increased by 22% YoY and by 11% from the previous quarter

What is Sage Therapeutics's growth rate over time

What is Sage Therapeutics stock price valuation

P/E

N/A

P/B

0.75

P/S

4.9

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

3.91

Sage Therapeutics's EPS has increased by 25% YoY and by 12% from the previous quarter

The P/B is 67% less than the 5-year quarterly average of 2.3 and 45% less than the last 4 quarters average of 1.4

SAGE's equity is down by 36% YoY and by 11% from the previous quarter

SAGE's P/S is 98% below its 5-year quarterly average of 258.4 and 86% below its last 4 quarters average of 35.7

The revenue has increased by 7% from the previous quarter

How efficient is Sage Therapeutics business performance

Sage Therapeutics's ROS has soared by 92% YoY and by 17% from the previous quarter

The ROIC has contracted by 26% YoY

Sage Therapeutics's ROE has decreased by 21% YoY

SAGE's ROA is down by 18% year-on-year

What is SAGE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SAGE.

How did Sage Therapeutics financials performed over time

The total assets has declined by 36% year-on-year and by 9% since the previous quarter

Sage Therapeutics's total liabilities has decreased by 29% YoY but it has increased by 12% QoQ

The company's debt is 100% lower than its equity

The debt to equity has plunged by 100% YoY

The company's debt has shrunk by 84% YoY and by 57% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.